Irish haematologist @stjamesdublin interested in lymphoma, myeloma, cell therapies, chromatin.Alum @TrinityMed1 , @tcdgenmicro, @pmcancercentre 🇮🇪🇨🇦
Dublin City, Ireland
Joined November 2019
- Tweets839
- Following1.1K
- Followers666
- Likes4.3K
Pinned Tweet
🧵1/Exciting news in cancer epigenetics! Our latest research, "AEBP2-Directed H3K27me2 Defines a Specific Vulnerability in EZH2-mutant Lymphoma", is now available on biorxiv.org/content/10.1101/…. Here's a thread with our findings!👇
#CancerResearch #Epigenetics #Chromatin #Lymphoma
James Nolan retweeted
This investment in digital capability represents a once-in-a-generation opportunity to modernise Ireland’s health infrastructure, delivering safer, smarter and more connected care for decades to come.
gov.ie/en/department-of-heal…
James Nolan retweeted
1/ It's long been assumed that AEBP2 recruit PRC2 to chromatin. Now, we show that AEBP2 usually does the exact opposite:
The only isoform of AEBP2 that is expressed in most cell types and tissues inhibits the chromatin-binding activity of PRC2. embopress.org/doi/full/10.10…
James Nolan retweeted
1/ 🚀 AEBP2 isn’t what we thought.
You were told that AEBP2 promotes PRC2 activity on chromatin. We found the opposite: the most prevalent AEBP2 isoform inhibits PRC2 activity.
Excited to share our new paper surl.li/cgwqcq
A thread 🧵
James Nolan retweeted
Putting off the tweetorial for a later date, but on behalf of the rest of our team, @Eddie_Cliff and I are super happy to share our polatuzumab x cell-of-origin study, out now online @CCR_AACR
doi.org/10.1158/1078-0432.CC…
@WashUOncology @SitemanCenter
Pleased to present at #ESMO25 the 16 year experience of tandem high-dose chemotherapy and autologous stem cell transplant for relapsed/refractory advanced stage germ cell tumours from @pmcancercentre .
n=71 patients with median follow-up 6.4 years. 2-year PFS/OS 52.1%/73.4%. No PFS events after 2 years. Platinum-refractoriness prior to ASCT median PFS <6 months = significant unmet need in R/R testicular GCT in need of alternative approaches.
Thank you to PI Prof Michael Crump and co-authors Prof John Kuruvilla, Dr Anca Prica, Dr Abi Vijenthira, Dr Sita Bhella, Dr Robert Kridel, Dr @DiMariaJiang , Dr Esmail Al-Ezzie, Dr Malcolm Moore, Prof Padraig Warde, Dr @RHamiltonUrol , Prof @Philippe_Bedard
James Nolan retweeted
Absolutely delighted to share our preprint, using functional genomics to uncover a novel dependency in lymphoma that can overcome resistance to targeted therapy. Very grateful to co-first author @JMNolan89 and co-senior authors @conwayer1 and @adrianbracken see thread 👇
🧵1/Exciting news in cancer epigenetics! Our latest research, "AEBP2-Directed H3K27me2 Defines a Specific Vulnerability in EZH2-mutant Lymphoma", is now available on biorxiv.org/content/10.1101/…. Here's a thread with our findings!👇
#CancerResearch #Epigenetics #Chromatin #Lymphoma
14/ We believe our findings offer significant insights for both basic and clinical research. By understanding the role of H3K27me2 in PRC2 dysfunction, we can explore new treatments for EZH2-dependent cancers. 🏥
15/ This work complements our previous research on CBX4 and H3K27M-mutant DMG [tinyurl.com/ev6drrya], showing how different forms of PRC2 dysfunction can be targeted in distinct cancer contexts. 🔍
